Cargando…
A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab
Since the beginning of the pandemic, numerous national and international clinical trials have been conducted with a large number of drugs. Many of them are intended for the treatment of other pathologies; however, despite the great effort made, no specific drug is available for the treatment of the...
Autores principales: | Villaescusa, Lucinda, Zaragozá, Francisco, Gayo-Abeleira, Irene, Zaragozá, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784859/ https://www.ncbi.nlm.nih.gov/pubmed/35072887 http://dx.doi.org/10.1007/s12325-022-02042-3 |
Ejemplares similares
-
Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1
por: Zaragozá, Cristina, et al.
Publicado: (2021) -
Flavonoids: Antiplatelet Effect as Inhibitors of COX-1
por: Zaragozá, Cristina, et al.
Publicado: (2022) -
Potential Therapeutic Anti-Inflammatory and Immunomodulatory Effects of Dihydroflavones, Flavones, and Flavonols
por: Zaragozá, Cristina, et al.
Publicado: (2020) -
Experience with the use of siltuximab in patients with SARS-CoV-2 infection
por: Meira, Fernanda, et al.
Publicado: (2021) -
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
por: Palanques-Pastor, Tomás, et al.
Publicado: (2020)